For cancer patients, the biggest nightmare is hard work and anti-cancer. After pains and hardships, the disease is hard to get control, and it doesn't last long for the tumor to come back again.
If there is a technology that allows patients to restore their own anti-tumor ability and form long-term memory, just like vaccination, in theory, patients will be able to return to health and stay away from cancer forever.
The exciting thing is that medical researchers have finally done this! Developed by the top research team of the University of Southern California's Norris Comprehensive Cancer Research Center, a distinguished medical school in the United States, Baylor College of Medicine, and the famous cancer research center in the United States, developed a powerful tumor called PD-L1. Vaccine (iPD-L1-Vax).
This new vaccine combines the most mainstream PD-1/PD-L1 immunological checkpoint technology and tumor-specific antigen recognition technology to achieve a broad-spectrum anticancer effect without distinguishing cancerous species.
Beginning in 2016, the research team invited patients with different cancer types to participate in clinical trials, including lung cancer, breast cancer, cervical cancer, colorectal cancer, esophageal cancer, prostate cancer, kidney cancer, nasopharyngeal cancer, bladder cancer, gallbladder cancer, etc. More than 450 patients with malignant tumors. The vast majority of patients have no obvious side effects, which confirms the safety of the application of this technology, and most patients have achieved good results after using this technology and established long-term anti-tumor immunity.
Principle of action of anti-PD-L1 potent tumor vaccine (iPD-L1-Vax)
The healthy population's own immune system has the function of identifying and eliminating foreign harmful substances and abnormal cells. Tumor cells want to survive in the human body, and must constantly evolve to avoid the identification and attack of the immune system.
Many tumor cells have evolved functions of overexpressing PD-L1 immunosuppressive molecules during the game with the immune system. By binding to PD-1 molecules on human immune cells, the immune cells of the human body are gradually inactivated, resulting in the body. Anti-tumor immunity is severely inhibited.
The anti-PD-L1 potent tumor vaccine (iPD-L1-Vax) combines dendritic DC cell loading technology with PD-L1 recombinant protein technology to block PD-L1 antibodies in the body and block PD-of tumor cells. The binding of L1 molecule to the PD-1 molecule of immune cells, thereby relieving the inhibition of the immune system by tumor cells, and restoring the ability of the human immune system to recognize and clear tumor cells. At the same time, the anti-PD-L1 potent tumor vaccine can also stimulate the clonal proliferation of tumor-specific killer cells in the human body, and enhance the ability of the human body to clear tumor cells.
Four major functions of anti-PD-L1 potent tumor vaccine (iPD-L1-Vax)
De-immunization inhibition: A potent tumor vaccine can stimulate the body to produce PD-L1 antibody, prevent PD-L1 molecules on the surface of tumor cells from binding to PD-1 molecules on the surface of immune cells, and block PD-1 and PD-L1 pathways. The inhibition of the immune system by cancerous cells is relieved, and the cancerous cells are prevented from immune escape by PD-L1.
Improve immunity: A potent tumor vaccine can release a strong anti-tumor signal to the body by increasing the number of signaling cells, stimulating the body's anti-tumor immune cell clonal proliferation, and improving anti-tumor immunity.
Complete removal of tumors: In addition to stimulating the proliferation of autoimmune cells, potent tumor vaccines can additionally supplement the body with a large number of tumor-specific antigen-killing cells by targeting tumor-specific antigens. These cells can accurately identify and completely remove tumor cells scattered throughout the body, achieving rapid and direct resistance to tumor treatment.
Long-term immune memory: tumor vaccine can stimulate immune cells to differentiate into specific memory cells, so that the body produces long-term immune memory. When new malignant cells express PD-L1, they will trigger an immune response to identify and clear them.
Four advantages of anti-PD-L1 potent tumor vaccine (iPD-L1-Vax)
Broad spectrum (applicable to most tumors): PD-L1 is used as a therapeutic target for almost all tumor diseases without distinguishing the type and stage of the tumor.
Long-term (establishing long-term immune memory): The vaccine can help the body to establish long-term immune memory of tumor cells. When tumor cells reappear in the human body, it will stimulate the body's immune system to produce specific killer cells to achieve recognition of tumor cells. And clear.
Accurate (directional removal of tumor cells): Vaccine-activated immune cells can accurately identify and remove tumor cells that are free in blood and tissues without harming normal human cells.
Rapid (direct killing of tumor cells): The vaccine stimulates the body to produce tumor-specific killer T cells, which can contact and directly lyse tumor cells with high expression of PD-L1 to achieve rapid and complete elimination of tumor cells.
How to apply anti-PD-L1 potent tumor vaccine and cancer treatment
Combination therapy: The anti-PD-L1 potent tumor vaccine can be combined with conventional treatments such as surgery, radiotherapy, chemotherapy and targeted therapy, which can quickly reconstruct the patient's immune system ability and effectively improve the postoperative anti-infective ability of patients. Enhance the clinical efficacy of surgery, chemotherapy, radiotherapy and targeted therapy, improve the quality of life of patients with cancer, and prolong the life of patients with advanced cancer.
Prevention of recurrence: Anti-PD-L1 potent tumor vaccine can induce long-term anti-tumor immune memory. When the body has new tumor cells, it will quickly initiate immune response, accurately identify and eliminate new cancerous cells, and effectively prevent tumor recurrence and metastasis. Move the treatment forward to avoid the patient's health and life being threatened again.
Independent treatment: anti-PD-L1 potent tumor vaccine can stimulate the body to produce a large number of tumor-specific killer cells, supplement the number and targeting ability of tumor-specific killer cells, and efficiently identify and remove tumor cells, which can not be operated, chemotherapy and chemotherapy The patient offers a completely new treatment plan.
Anti-PD-L1 potent tumor vaccine (iPD-L1-Vax) clinical case
Case 1
Lymphoma patients treatment effect
Patient female, 48 years old, lymphoma. After immunotherapy, PET/CT showed multiple metabolically active lymph nodes in the supraclavicular, mediastinal and bilateral hilars, and the metabolic activity was significantly reduced. The imaging results showed that the tumors on both sides of the lymphoma patients who were resistant to chemotherapy after 83 days of cell infusion disappeared "abruptly".
Case 2
Therapeutic effect of patients with prostate cancer with bone metastasis
Patients with prostate cancer with bone metastases. After treatment, the PSA value of prostate cancer tumor markers decreased from 940.9 before treatment to 0.86 after treatment. Bone metastasis and pain disappeared.
Effect icon:
Tumor-specific killer cell activation
Effect icon:
Vaccine inhibits breast cancer growth
Effect icon:
Vaccine inhibits prostate cancer growth
Anti-PD-L1 potent tumor vaccine (iPD-L1-Vax) technical cooperation
The anti-PD-L1 potent tumor vaccine was developed by Baylor College of Medicine, a leading medical school in the United States, and the Norris Comprehensive Cancer Research Center of the University of Southern California.
It is currently the only tumor vaccine in the world that can improve the body's own immune system to recognize and kill tumor cells, and prevent tumor recurrence and metastasis. Its recombinant protein and vaccine preparation technology has obtained patent protection from the State Intellectual Property Office of China, and is a unique and innovative product and technology in the field of cancer treatment and prevention.
At present, the anti-PD-L1 potent tumor vaccine technology has attracted extensive attention from many research institutions and experts at home and abroad, and has been among the top three authoritative authorities in China, including the Cancer Hospital of Sun Yat-sen University, the Cancer Hospital of Guangzhou Medical University, and the Cancer Hospital of Chongqing. The hospital and the Cancer Research Center conduct clinical research cooperation. We can use Ion Torrent high-throughput sequencing technology and bioinformatics analysis technology to provide accurate detection of tumor immunity for cancer patients and high-risk groups, and to serve individualized human health and tumor diagnosis and treatment.
Greenhouse Film Electric Roll Up
The Greenhouse Film Manual Roll Up Unit can roll up a length of 60-80 meter, running stably with fine out side looking and long time of usage. The inside drive gears are made of high quality steel with fine workmanship, and what is more, there is lubricating bearing assembled on the out put and input shaft. At the meantime, there is also a group of reverse gear added to it. All these make the unit to be light and easy for
Greenhouse Film Electric Roll Up,Roll Up Curtain Greenhouse,Greenhouse Film Vent Roller,Greenhouse Roll Up Motor
JIANGSU SKYPLAN GREENHOUSE TECHNOLOGY CO.,LTD , https://www.spgreenhouse.com